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Abstract 23 
Objectives: An affordable and effective treatment is needed to manage feline 24 
hypersomatotropism / acromegaly. The study aim was to assess whether treatment with 25 
oral cabergoline for 90 days in cats with hypersomatotropism and diabetes mellitus 26 
improves diabetic and insulin-like growth factor 1 control.  27 
Methods: Prospective cohort non-blinded pilot study enrolling client owned cats with 28 
spontaneously occurring diabetes mellitus and hypersomatotropism. Cats received oral 29 
cabergoline (5 to 10 µg/kg q24 h) for 90 consecutive days. Serum insulin-like growth 30 
factor 1 and fructosamine concentrations were measured on days 1, 5, 30 and 90. 31 
Quality of life was determined using the DIAQoL-pet questionnaire on days 1 and 90. 32 
Results: Nine cats were enrolled and eight completed the study. There was no 33 
significant change of insulin-like growth factor 1 (day 1 median was 2001 [range 890 to 34 
2001]; day 30 median was 2001 [range 929 to 2001]; day 90 median was 1828 [range 35 
1035 to 2001] ng/mL (X2(2) = 0.667, P = 0.805), fructosamine (day 1 median was 499 36 
[range 330 to 887], day 30 median was 551 [range 288 to 722], day 90 median was 503 37 
[range 315 to 851] µmol/L, X2(2) = 0.581, P = 0.764), or DIAQoL-pet score (median on 38 
day 1 was -2.79 [range -4.62 to – 0.28], median on day 90 was -3.24 [range -4.41 to -39 
0.28], P = 0.715). There was a significant change of insulin dose (X2(2) = 8.667, P = 0.008) 40 
with cats receiving higher insulin doses at day 90 compared to day 1 (median day 1 was 41 
 4 
0.98 [range 0.63 to 1.49] and median day 90 was 1.56 [range 0.49 to 2.55] units/kg q12h, 42 
P = 0.026. 43 
Conclusions and relevance: Cabergoline did not improve diabetic or normalise insulin-44 
like growth factor concentration, nor improve patient quality of life.  45 
 46 
 5 
Introduction: 47 
Hypersomatotropism (HST) in cats is a condition caused by chronic excessive 48 
growth hormone (GH). Most cats with HST have concurrent diabetes mellitus (DM) 49 
which can be difficult to control using treatments which only target glycemic 50 
control.  51 
 52 
Medical management using pasireotide or surgical management via 53 
hypophysectomy has improved GH and diabetic control in cats with HST.1–3 54 
However, these treatments are often too costly for owners and effective alternative 55 
modalities are needed.  56 
 57 
In human medicine, HST is known as acromegaly due to the phenotypic changes 58 
induced by the condition. There are three main medical management options for 59 
acromegaly in humans which are somatostatin receptor agonists (SRAs) such as 60 
octreotide or pasireotide, dopamine receptor agonists (DRAs) such as 61 
bromocriptine or cabergoline and growth hormone receptor antagonists, namely 62 
 6 
pegvisomant. Recommendations suggest the primary medical treatment of patients 63 
who have moderate-to-severe disease should be SRAs and patients who have mild 64 
disease (serum insulin-like growth factor 1 [IGF1] < 2 times the upper limit of the 65 
age adjusted range) can be treated using a DRA.4,5 The direct mechanism of action 66 
of GH-secretion inhibition by DRAs is thought to be via somatotrope dopamine 2 67 
receptors (D2Rs) within the pituitary.6 As cats with HST have pituitary expression of 68 
D2R, therapy with a DRA might result in improved GH control and therefore 69 
diabetic control.7 70 
 71 
Cabergoline and bromocriptine are DRAs with high affinity for D2R in rats and 72 
monkeys8,9. Cabergoline is the D2R-specific DRA with more favourable properties, 73 
having a longer action of duration and thus requires less frequent dosing, is better 74 
tolerated and exhibits increased insulin sensitising effects independent of GH 75 
reduction compared to bromocriptine.10,11 An oral preparation of cabergoline was 76 
licensed and available for use in cats at the time of study (Kelactin, Kela N.V.) 77 
Cabergoline has also been proven to be well tolerated when administered for 78 
 7 
several months in both dogs and humans.12,13 79 
 80 
The aim of the pilot study was to determine if cats with HST and DM experienced 81 
decreased serum IGF1 and improved diabetic control determined by serum 82 
fructosamine concentration and insulin dose requirement when receiving once 83 
daily treatment with oral cabergoline. A secondary aim of the study was to 84 
determine whether this treatment resulted in improved quality of life of these cats. 85 
 86 
Materials and methods 87 
The study was approved by the Ethics and Welfare Committee of the Royal 88 
Veterinary College, UK; URN 2016 1604. Informed written consent was obtained 89 
from all owners before enrolment. Cats with HST were prospectively enrolled 90 
between 01/10/2016 and 31/05/2017. Inclusion criteria were DM which had been 91 
treated for at least four weeks prior to enrolment, serum IGF1 concentration >700 92 
ng/mL with pituitary enlargement (>4mm dorsoventral height) or serum IGF1 93 
>1000 ng/mL without pituitary imaging. Since IGF1 >1000 ng/mL has been shown 94 
 8 
to have a positive predictive value for HST of 95% in the UK diabetic cat population 95 
where the prevalence of HST was 25%, necessity of additional pituitary imaging in 96 
this group was not deemed essential.14 If contrast enhanced pituitary imaging had 97 
not already been performed and the owner consented to the procedure, then this 98 
was undertaken on day 1 as previously described.15 Exclusion criteria were poor 99 
patient tolerance of veterinary procedures, uncontrolled hyperthyroidism, insulin 100 
antagonist therapy within the preceding four weeks prior to enrolment or if they 101 
had a disease which was more critical to the cat’s welfare than HST as judged by 102 
the attending clinician.  103 
 104 
Owners of eligible cats were offered a reduced fee for contrast enhanced CT of 105 
their cat, free supply of PZI insulin (Prozinc, Boehringer Ingelheim) and diabetic cat 106 
food (Purina DM, Nestle Purina) for the length of the study. Owners paid for the 107 
initial period of hospitalization and the cost of cabergoline during the study. 108 
Owners were encouraged to perform home blood glucose monitoring.  109 
 110 
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On day 1, a blood sample was collected for pre-treatment CBC, serum 111 
biochemistry, serum IGF1 and fructosamine concentration determination. Cats had 112 
a subcutaneous interstitial glucose monitor (Guardian REAL Time Continuous 113 
Glucose Monitoring System, Medtronic) placed to measure glycemic control for an 114 
initial period of hospitalization of four days17. Cats received the same insulin dose 115 
and frequency as prescribed by their referring veterinarian prior to enrolment on 116 
day 1, cats were prescribed oral cabergoline once daily starting on day 2 and were 117 
discharged on day 5. Cats were monitored for possible adverse drug effects, 118 
whether there was increased sensitivity to insulin therapy as determined by 119 
glycemic control during hospitalization, clinical sign monitoring by their owners 120 
and repeat fructosamine measurement on days 30 and 90, and IGF1 measurements 121 
were repeated on days 30 and 90 (Figure 1). 122 
 123 
Patient quality of life (QoL) was assessed by requesting owners to complete the 124 
psychometric DIAQoL-pet questionnaire at day 1 and 90. The DIAQoL-pet has 125 
previously been validated to quantify owner perceived QoL of diabetic pet and 126 
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owner, and can quantify the effect of treatment upon their diabetic cat’s quality of 127 
life as well as their own.18  128 
 129 
Statistical Analysis 130 
A P value < 0.05 was considered significant. Data were analysed for normal 131 
distribution visually using histograms and by performing Shapiro–Wilk tests. Any 132 
IGF1 concentration > 2000 ng/mL was analysed as being 2001 ng/mL. Non-133 
normally distributed data are presented as median and range and data with 134 
normally distributed data presented as mean and standard deviation (S.D.). 135 
Friedman tests and post-hoc related samples Wilcoxon signed rank tests with 136 
Bonferroni adjustment where appropriate were performed to compare repeated 137 
measures IGF1, fructosamine and insulin dose data on days 1, 30 and 90. Related 138 
samples Wilcoxon signed rank test was used to compare QoL data on days 1 and 139 
90. The Spearman rank test was used to compare the strength of correlation 140 
between data. Statistical analyses were performed using statistical software 141 
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(GraphPad Prism version 8.4.0 for macOS, GraphPad Software and IBM SPSS 142 
Statistics Version 26.0.0.0 for macOS, IBM Corp). 143 
 144 
Results 145 
Nine cats were enrolled, eight cats completed the study and one cat (cat 1) died 146 
during the study. The data from the cat which did not complete the study was 147 
excluded from these analyses of insulin dose, fructosamine, IGF1 and DIAQol-pet 148 
scores. All nine cats were DSH breed, six were male and three were female, the 149 
mean age was 10.8 years (S.D. 2.8), mean weight was 4.8 kg (S.D. 0.8), mean 150 
pituitary dorsoventral height was 6.3 mm (S.D. 1.6) and median pituitary volume 151 
was 0.088 cm3 (range 0.048 to 0.327). Cat 6 did not undergo intracranial CT 152 
imaging because of the concern this patient had a high risk for congestive heart 153 
failure as determined by echocardiographic measurements. Home blood glucose 154 
monitoring was performed by 4/9 owners. All owners reported they were successful 155 
when giving cabergoline to their cats and that the medication had been handled 156 
per manufacturer’s instructions. 157 
 12 
 158 
The first three cats enrolled on the study received 5 μg/kg cabergoline q24h but 159 
had a dose increase to 10 μg/kg q24h at day 30 to 35, and the remaining cats had 160 
a cabergoline dose of 10 μg/kg q24h from enrolment. Cat 7 did not have IGF1 and 161 
fructosamine measurements at day 30.  162 
 163 
Serum IGF1 results 164 
There was no significant change of serum IGF1 concentration over the three 165 
months of the study (day 1 median was 2001 [range 890 to 2001]; day 30 median 166 
was 2001 [range 929 to 2001]; day 90 median was 1828 [range 1035 to 2001] 167 
ng/mL, X2(2) = 0.667, P = 0.805) (Figure 1). Four experienced a decrease and four 168 
an increase IGF1 from day 1 to day 90. The median pituitary volume of cats which 169 
experienced IGF1 reduction was not significantly different to those who did not 170 
experience a reduction of IGF1 (0.086 vs and 0.133 cm3, P = 0.94). 171 
 172 
Serum fructosamine and insulin dose 173 
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There was no statistical difference of fructosamine concentration at any time point 174 
(day 1 median was 499 [range 330 to 887], day 30 median was 551 [range 288 to 175 
722], day 90 median was 503 [range 315 to 851], X2(2) = 0.581, P = 0.764) (Figure 176 
2). An insulin dose increase was prescribed for 6/8 cats. There was a significant 177 
change of insulin dose prescribed during the study (X2(2) = 8.667, P = 0.008), with 178 
cats receiving higher insulin doses on day 90 compared to day 1 (median day 1 was 179 
0.98 [range 0.63 to 1.49] and median day 90 was 1.56 [range 0.49 to 2.55] units/kg 180 
q12h, P = 0.026.) (Figure 3). 181 
 182 
DIAQol-pet scores 183 
The DIAQol-pet was completed by 6/8 owners of cats. There was no statistical 184 
change of DIAQoL-pet scores between day 1 and day 90 (median on day 1 was -185 
2.79 [range -4.62 to – 0.28], median on day 90 was -3.24 [range -4.41 to -0.28], P = 186 
0.715), (Figure 4). DIAQoL-pet scores negatively correlated with insulin dose on day 187 
1 but not on day 90 (Spearman’s rank -0.871, P = 0.034 and -0.257, P = 0.623, 188 
respectively).  189 
 14 
 190 
Potential adverse drug effects 191 
One cat died during the study period (cat 1 in Supplemental Table 1). General 192 
physical examination at enrolment of this cat was unremarkable apart from a grade 193 
2/6 systolic cardiac murmur. An echocardiogram was not performed at enrolment. 194 
On day 82, the cat developed tachypnoea and was diagnosed with supraventricular 195 
tachycardia and congestive heart failure. The cat’s owners elected for him to be 196 
euthanized and a post-mortem examination was declined.  197 
 198 
Cat 7 did not have fructosamine or IGF1 data for day 30 because he was 199 
hospitalized at his local veterinary practice for an episode of presumed pancreatitis 200 
on day 28. Cat 5 experiencing reduced appetite and small intestinal diarrhea which 201 
resolved within one week without specific treatment, and the same cat experienced 202 
asymptomatic hypoglycemia on day 60. Two other cats experienced self-limiting 203 
inappetence of unknown cause lasting less than one week. No owner requested 204 
withdrawal from the study due to concern of possible adverse drug effects. 205 
 15 
 206 
Discussion 207 
This is the largest case series to-date to describe cats with HST and DM treated 208 
with cabergoline. Although a direct measurement of insulin sensitivity was not 209 
performed, the trend for increasing requirement for exogenous insulin with similar 210 
serum fructosamine concentrations infers the cats experienced increasing insulin 211 
resistance. This is likely due to ongoing uncontrolled HST because cabergoline did 212 
not reliably control IGF1 concentration by decreasing it to within the reference 213 
interval. 214 
 215 
There are no published studies describing the pharmacokinetics of cabergoline in 216 
cats. The plasma elimination half-life is between 63 to 109 hours in humans.8 The 217 
initial dose of 5 μg/kg q24h by mouth was chosen because this was the licensed 218 
dose for the treatment of inappropriate lactation in cats, and this dose was 219 
effective in terminating pregnancy in queens which suggests effective suppression 220 
of prolactin secretion.19 This dose is equivalent to 0.5 mg q24h dose for an average 221 
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human using mg/kg dosing, which is reported to result in GH suppression in 222 
humans with acromegaly.20 However, other studies have reported using higher 223 
doses of cabergoline to treat cats and the medication was well tolerated, and some 224 
humans with acromegaly require higher doses to achieve biochemical response.21,22 225 
This was part of the rationale for increasing the initial cabergoline dose from 5 to 226 
10 μg/kg q24h for cats 4 to 9.  227 
 228 
The findings of this study differ from the results of a case series of three cats with 229 
HST and DM treated with 10 μg/kg q48h cabergoline for three months.23 All the 230 
cats in that study experienced decreased IGF1 and improved insulin sensitivity after 231 
treatment. It is possible that the cause of HST in cats was different to the cause of 232 
HST in this study as different pituitary adenoma subtypes are known to respond 233 
differently to medical management.24,25 Response to cabergoline therapy can also 234 
vary depending on prior treatments, alternative splicing of DRD2 mRNA, 235 
magnitude of dopamine receptor expression at the protein level or defective 236 
signalling pathways downstream of DR2 stimulation. 26–29 It has been reported that 237 
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cats with hypersomatotropism have a moderate negative correlation between 238 
DRD2 expression and pituitary size7. That data suggests that pituitary size might be 239 
related to cabergoline responsiveness, but there was no difference of pituitary size 240 
between those who experienced an IGF1 decrease versus those who did not in this 241 
study. The low number of patients enrolled on this study will be a limiting factor to 242 
identify the effect of pituitary size and cabergoline responsiveness. A study 243 
investigating the effect of DR2 protein expression and cabergoline responsiveness 244 
is indicated to better determine the variability of cabergoline effect between 245 
patients.  246 
 247 
Cabergoline is typically recommended for the treatment of acromegaly in humans 248 
who have mild clinical signs and IGF1 concentrations less than 1.5 to 2 times above 249 
the reference interval.5,30 There were 6/9 cats who had serum IGF1 concentrations > 250 
2000 ng/mL at the start of the study and only two cats had IGF1 concentrations less 251 
than twice the laboratory reference interval. It is possible that the severity of HST in 252 
these cats was inappropriate for cabergoline treatment. Apart from decreasing 253 
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IGF1, cabergoline might exert antidiabetic effects by increasing insulin sensitivity 254 
without affecting GH levels.31 This mechanism could explain the response of cat 5 255 
who was receiving a lower dose of insulin and had lower serum fructosamine 256 
despite slightly increased IGF1 at day 90 compared to day 1. 257 
 258 
Consideration and measurement of QoL is increasingly important when 259 
undertaking clinical studies and particularly important in veterinary medicine as a 260 
common reason for euthanasia of a cat with DM is owner perceived poor pet 261 
QoL.32–34 Acromegaly is associated with reduced QoL in humans and improves but 262 
does not normalize with disease control.35–38 Diabetes in cats is associated with 263 
owner perceived reduced QoL of their cat and improved DM control has been 264 
associated with improved QoL.18,39 Quality of life scores did not improve during the 265 
study which could be explained due to poor biochemical control of either HST or 266 
DM.  267 
 268 
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Clinical signs that might have been compatible with drug-induced adverse effects 269 
include an episode of presumed acute pancreatitis in one cat, 2/9 cats experienced 270 
inappetence presumed not associated with pancreatitis and one cat, which had 271 
experienced inappetence, also experienced self-limiting small intestinal diarrhoea 272 
lasting less than one week. Gastrointestinal adverse effects of cabergoline have 273 
previously been reported in cats receiving 15 μg/kg q24h.21 Nausea and vomiting 274 
and vertigo are the most commonly reported side effects in cabergoline treated 275 
humans with hyperprolactinaemia, affecting up to 1/3 of those treated.40 276 
Cabergoline does not appear to induce pancreatitis in humans, and it is possible 277 
the cat which experienced pancreatitis did so independent of cabergoline 278 
treatment. Pancreatic pathology in cats with DM appears to be common. One study 279 
reported 83 % of diabetic cats having increased feline-specific pancreatic lipase 280 
activity (fPLI), which is a marker of pancreatic inflammation.40 Post-mortem 281 
examinations of cats with DM describe up to half of patients having evidence of 282 
chronic pancreatitis and 5 % having evidence of acute pancreatitis at the time of 283 
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death.41 Additional studies are required to determine if cabergoline treatment is 284 
associated with pancreatitis in cats. 285 
 286 
In 2008, the Medicine and Healthcare products Regulatory Agency published a 287 
statement that cabergoline therapy might be associated with increased risk of 288 
cardiac fibrosis, and cardiac valvulopathy should be excluded prior to starting 289 
cabergoline therapy.41 A recent systematic review concluded that the risk of 290 
cabergoline-associated valvulopathy in patients with prolactinoma is low, but the 291 
authors recommend an initial echocardiogram prior to starting cabergoline 292 
therapy.42 Patient’s affected by Parkinson’s disease often receive cabergoline doses 293 
greater than 3 mg per day (around 40 μg/kg q24h for the average UK human) 294 
compared to 0.25 to 3 mg/week (equating to 3.125 to 39 μg/kg per week) in 295 
patients affected by prolactinoma and appear to have an increased risk of 296 
cabergoline induced cardiomyopathy.43–45 The doses of cabergoline used in this 297 
study are more comparable with those used to treat prolactinoma than Parkinson’s 298 
disease. Nonetheless, as 30 to 50 % of apparently healthy cats without a heart 299 
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murmur have echocardiographic evidence of heart disease, it is possible that the 300 
use of cabergoline might have contributed to progressive cardiac disease in patient 301 
1 who died on day 82.46,47 It is also possible this patient experienced progressive 302 
heart disease regardless of cabergoline therapy because HST in cats is associated 303 
with a hypertrophic cardiomyopathy phenotype and increased risk of congestive 304 
heart failure.48 As a result of the death of this patient, all subsequently enrolled 305 
patients underwent echocardiogram examination at enrolment and risk of 306 
progressive cardiac disease was discussed with owners. Owners were instructed to 307 
intermittently monitor their cat’s resting respiratory rate at home because this is 308 
reported to be a sensitive indicator of congestive heart failure in cats.16 Owners 309 
were instructed to contact the investigator if their cat’s average resting respiratory 310 
rate was greater than 36 breaths per minute. No owner declined to enrol on the 311 
study after receiving this information and no further increased resting respiratory 312 
rate events occurred during the study period. 313 
 314 
 315 
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The low patient number will have affected the power of the study. However, this 316 
was a pilot study and as a previous report described a good response of three cats 317 
with diabetes and hypersomatotropism treated with cabergoline, this study 318 
provides evidence that not all cats experience a good response.23 Another 319 
limitation is that IGF1 concentrations greater than 2000 ng/mL were not diluted to 320 
obtain the exact IGF1 concentration. The lack of exact IGF1 enumeration will have 321 
limited our ability to determine a difference during the study. We wished to assess 322 
whether good control, as defined as IGF1 concentration within the reference 323 
interval, would be achieved. Nonetheless, despite this limitation we can be 324 
confident reporting that no cat achieved normalization of serum IGF1. 325 
 326 
Conclusion 327 
Although the study was underpowered, cabergoline does not appear to reliably 328 
control HST as the cats in this study did not achieve IGF1 control nor improved 329 
diabetic control.  330 
 331 
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Figures  476 
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Figure 1. Patient serum IGF1 at time points day 1, 30 and 90. There was no significant 479 
change of insulin-like growth factor 1 during the study (X2(2) = 0.667, P = 0.805).  480 
 481 
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Figure 2. Patient serum fructosamine at time points day 1, 30 and 90. There was no 485 
significant change of fructosamine during the study, X2(2) = 0.581, P = 0.764).  486 
 487 
 488 
 36 
Figure 3. Patient insulin dose at time points day 1, 30 and 90. There was a significant 489 
change of insulin dose prescribed during the study (X2(2) = 8.667, P = 0.008), with cats 490 
receiving higher insulin doses on day 90 compared to day 1 (median day 1 was 0.98 491 
[range 0.63 to 1.49] and median day 90 was 1.56 [range 0.49 to 2.55] units/kg q12h, P = 492 
0.026.)  493 
 494 
 495 
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Figure 4. Patient DIAQoL-pet scores on days 1 and 90. There was no significant change 496 
of DIAQol-pet score (P = 0.715).  497 
 498 
 499 
